Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
459789-99-2
Molecular formula
C26H44O4
Molecular weight
420.6 g/mol
Drug class
Farnesoid X receptor (FXR) agonistbile-acid analogue
Mechanism of action
Activates FXR in the liver and intestine, regulating bile-acid synthesis and transport and reducing hepatic bile-acid accumulation. It also modulates pathways involved in lipid and glucose metabolism.
Indications / reported uses
Historical US indication: treatment of primary biliary cholangitis in adults in combination with ursodeoxycholic acid when response to UDCA is inadequate, or as monotherapy when UDCA is not tolerated. US FDA accelerated approval was withdrawn in 2025; do not present as currently authorised in the US.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Obeticholic Acid Environmental Risk Assessment (ERA) (the Obeticholic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.